je.st
news
Tag: interim
IFF To Appoint OLeary Interim CFO
2014-11-14 06:00:00| Happi Breaking News
EVP & CFO Berryman steps down.
Invitation to presentation of Bactiguard's interim report on November 14
2014-11-12 01:50:53| Appliances - Topix.net
Bactiguard Holding AB publishes the interim report for the third quarter on Friday 14 November at 08:00 CET In connection with this, a conference call for analysts and media will be held at 10:00 CEO on November 14. CEO Johan Rugfelt and CFO Fredrik Jarrsten will present the interim report and answer questions. The report will be available at Bactiguard's website www.bactiguard.com from 08:00 CET the same day.
Tags: report
november
presentation
interim
Interim AD Jim Hackett
2014-11-11 21:03:16| Furniture - Topix.net
Jim Hackett was appointed Michigan's interim director of athletics by president Mark Schlissel on Oct. 31, 2014. The recently retired chief executive officer of Michigan-based Steelcase Inc., Hackett will lead Michigan Athletics while a search for an AD is launched.
Interim Data from Proof-of-Concept Study of Merck's Investigational...
2014-11-10 08:38:26| Biotech - Topix.net
Merck , known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company's investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus infection.
Tags: data
study
interim
investigational
Interim Data from Proof-of-Concept Study of Mercks Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting
2014-11-10 00:53:00| Merck.com - Research & Development News
Dateline City: BOSTON Merck Plans to Initiate Phase 2 C-CREST Program to Evaluate Mercks Triple Combination of Grazoprevir/Elbasvir with MK-3682 (formerly IDX21437), a Novel Nucleotide Inhibitor, in Q1 2015 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the companys investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B) inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orSarra Herzog, 201-669-6570orInvestor:Joe Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
study
presented
Sites : [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] next »